XML 263 R206.htm IDEA: XBRL DOCUMENT v3.25.0.1
Income tax expense - Summary of Allocation of Income Tax Expense Between Current and Deferred Taxes (Details) - EUR (€)
€ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Income Taxes [Abstract]      
Current taxes € (2,152) € (2,251) [1] € (2,631) [1]
Deferred taxes 948 1,234 [1] 722 [1]
Total (1,204) (1,017) [1],[2] (1,909) [1],[2]
Income before tax and investments accounted for using the equity method € 6,698 € 6,251 [1],[2],[3] € 9,937 [1],[2],[3],[4]
Other items [5] 2.70% 2.60% [6] 1.30% [6]
[1] (a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued
operation.
[2] Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation
[3] (a)Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued
operation.
[4] 2022 business operating income has been recast from the amount previously reported to include the one-time income of €952 million from the Libtayo transaction (€706 million net of tax)
[5] In determining the amount of the deferred tax liability for 2024, 2023 and 2022, Sanofi took into account changes in the ownership structure of certain subsidiaries
[6] (a)Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued
operation.